Project Grant R37CA299623
Award Date 5/8/26
Completion Date 4/30/31
Dollars Obligated $639K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43205, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $608,558 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Research Institute at Nationwide Children's Hospital, effective April 2, 2026, through March 31, 2031. This fundamental cancer research initiative aims to advance understanding of high-risk neuroblastoma through the development of clinically relevant immunocompetent mouse models and the identification of metabolic vulnerabilities that can...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Van Andel Research Institute $153,114 on August 1, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to support research on targeting chromatin plasticity mechanisms to enhance the efficacy of epigenetic solid tumor therapy. The award funds an F99/K00 fellowship mechanism through September 1, 2027, enabling Principal Investigator Yanqing Liu to investigate how DNA methyltransferase (DNMT)...
- Federal Project Grant Award Summary Seattle Children's Hospital, doing business as Seattle Children's Research Institute, received a $636,097 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) for a five-year research initiative running from May 1, 2026, through April 30, 2031. The award funds fundamental research investigating the role of menin as a master regulator of Ewing sarcoma (EWS) cell stemness and metastatic potential. EWS...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $323,860 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Research Manpower program (CFDA 93.398) on August 18, 2025, with completion targeted for April 30, 2028. This award supports research investigating the role of mutagenic DNA repair pathways in cancer cell persistence and acquired drug resistance. The project focuses on understanding how cancer cells under stress from anti-cancer...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $901,205 to Boston Children's Hospital under the Cancer Treatment Research program (CFDA 93.395) effective July 3, 2025, with a completion date of June 30, 2032. This research initiative focuses on identifying genome-wide changes in gene expression during early tumorigenesis and metastatic progression to improve immunotherapy efficacy. The project leverages genetically engineered mouse models...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $406,258 to the Research Institute at Nationwide Children's Hospital (effective May 1, 2026 through April 30, 2028) under the Cancer Cause and Prevention Research program (CFDA 93.393). This award supports MEDMEMOS, a novel four-session adherence promotion intervention designed to improve medication compliance in pediatric allogeneic hematopoietic stem cell transplant (PAHCT) patients and their...
- Federal Project Grant Award Summary St. Jude Children's Research Hospital Inc. received a $3,032,826 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) effective September 1, 2025, with a completion date of August 31, 2030. This award supports the FUSONC Program Project, which investigates fusion oncoproteins (FOPs)—abnormal proteins arising from gene translocations that drive approximately 17% of all cancers and are particularly...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Grant Award Summary The National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) awarded Penn State Milton S. Hershey Medical Center a $690,013 Project Grant on August 11, 2025, to conduct fundamental research on extracellular vesicles (EVs) in neuroblastoma treatment and drug resistance. The five-year project, concluding July 31, 2030, will deliver research findings and scientific knowledge aimed at developing novel therapeutic strategies targeting tumor-derived EVs...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $530,106 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective September 11, 2025 through August 31, 2030. The project, "Targeting Polyamine Metabolism in Relapsed Acute Myeloid Leukemia Stem Cells," focuses on fundamental research to understand and mechanistically interrogate polyamine metabolism in leukemia stem cells (LSCs). The...